Senate rejects drug-importation proposal
The U.S. Senate voted down a plan Tuesday to allow Americans to import prescriptions from abroad, handing drug makers
such as Indianapolis-based Eli Lilly and Co. a victory.
Pharmaceutical
Articles
Lilly wins approval for long-acting Zyprexa
Once-a-month injection of best-selling drug will have patents that could extend until 2018.
Plainfield’s MD Logistics sued by Bristol-Myers over lost insulin
Two semi-trailers of the medication were stolen in 2007 from a back lot at Daum Trucking, which isn’t named in the lawsuit.
Bristol-Myers charges MD Logistics with negligence in the $10.7 million suit.
Eli Lilly’s shares slip after it forecasts mixed profits in coming years
The Indianapolis-based drugmaker predicts strong profits through 2011, but its forecast for 2012 suggests bottom-line results
could fall precipitously.
Lilly launching new venture capital fund
The fund would acquire experimental drugs and use Lilly R&D staff to try to prove their effectiveness, perhaps boosting Lilly’s drug pipeline.
Lilly forecasts growth in earnings next year
Eli Lilly and Co. said it still expects its earnings per share to grow in the double-digit range through 2011.
Ariad asks court to restore patent-suit win against Lilly
A federal appeals court will decide whether Eli Lilly and Co. must pay $65.2 million in damages, plus royalties, over a drug-patent
claim.
Legislators could test drugmakers’ support for health overhaul
The pharmaceutical industry may have to cough up more than the $80 billion it agreed to contribute to President Barack Obama’s
health overhaul effort, reflecting pressure from Democrats and their supporters for more money to cover older and low-income
people.
Builder looks to cold storage for steady work in a weak economy
Cold storage might become a hot business for a building contractor.
Part of Mississippi’s Zyprexa case against Lilly dismissed
Indianapolis-based Eli Lilly and Co. has won a bid to dismiss part of a negligence lawsuit brought by Mississippi that alleges
improper marketing of antipsychotic drug Zyprexa for unapproved uses.
Lilly extends research pact with India firm
Jubilant Organosys Ltd. and Indianapolis-based Eli Lilly and Co. extended their collaboration, which began in 2005, by five
years.
Lilly’s Cymbalta wins new approval for anxiety disorder
FDA action should boost sales of the Eli Lilly and Co. drug, which were already on pace to top $3 billion this year.
Lilly stock droops after rival claims faster-acting impotence pill
California-based Vivus claims its drug acts in 30 minutes, compared with about 2 hours for Lilly’s Cialis.
Aarden Pharmaceuticals chose Indianapolis over San Diego for headquarters
Thanks partly to a state grant and support from Indiana’s BioCrossroads life sciences initiative, principals “decided
locating here would give Aarden a better chance of success.
Lilly to pay Utah $24 million to settle Zyprexa suit
Eli Lilly and Co. has agreed to pay Utah $24 million to settle a lawsuit claiming the company improperly marketed the antipsychotic
drug Zyprexa.
Indiana among 15 states accusing Amgen of illegal kickbacks
Biotechnology behemoth Amgen Inc. is being sued by 15 states, including Indiana, alleging the company gave kickbacks to medical
providers to help boost sales of the Aranesp.
Lilly to move 1,000 from Faris campus
As it shrinks its work force, Indianapolis-based pharmaceutical firm Eli Lilly and Co. will move more than 1,000 employees to its corporate
center
by mid-2010.
Lilly settles Zyprexa case with S. Carolina for $45M
South Carolina Attorney General Henry McMaster said Friday that the state has reached a $45 million settlement with drug maker
Eli Lilly and Co. over the company’s marketing of an anti-psychotic drug.
Lilly needs to sell more Effient before Zyprexa loses patent protection
Sales of Eli Lilly and Co.’s newest drug were an afterthought during its Oct. 21 report on third-quarter earnings. The blood thinner Effient totaled up $22.6 million in sales—a mere 0.4 percent of Lilly’s total for
the quarter.
Eli Lilly CEO banking on new drug pipeline
CEO John Lechleiter says Lilly’s pipeline has helped it rebound from significant patent losses three times during his 30-year
career at the company. He’s betting there will be a fourth.